<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

	<channel><title><![CDATA[Latest Category Reports]]></title><atom:link href="http://www.researchmoz.com/pharmaceutical-and-healthcare-market-reports-1.xml" rel="self" type="application/rss+xml" />
	<link>http://www.researchmoz.com</link>
	<description><![CDATA[Latest Category Reports]]></description>
	<lastBuildDate>Wed, 18 Jul 2012 12:20:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator><item><title>Medical Dressings - American Markets Package</title><link>http://www.researchmoz.com/medical-dressings-american-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-american-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-american-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different American countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different American countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different American countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-american-markets-package-report.html>Medical Dressings - American Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different American countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different American countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different American countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-american-markets-package-report.html>Medical Dressings - American Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-american-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - African Markets Package</title><link>http://www.researchmoz.com/medical-dressings-african-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-african-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-african-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different African countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different African countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different African countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017
 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-african-markets-package-report.html>Medical Dressings - African Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different African countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different African countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different African countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017
 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-african-markets-package-report.html>Medical Dressings - African Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-african-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Asian Markets Package</title><link>http://www.researchmoz.com/medical-dressings-asian-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-asian-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-asian-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different Asian countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different Asian countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:

Adhesive medical dressings
Other medical dressings

Years covered: 2006 2017

Countries inc <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-asian-markets-package-report.html>Medical Dressings - Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different Asian countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different Asian countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:

Adhesive medical dressings
Other medical dressings

Years covered: 2006 2017

Countries inc <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-asian-markets-package-report.html>Medical Dressings - Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-asian-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Eastern European Markets Package</title><link>http://www.researchmoz.com/medical-dressings-eastern-european-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-eastern-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-eastern-european-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different Eastern European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different Eastern European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different Eastern European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-eastern-european-markets-package-report.html>Medical Dressings - Eastern European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different Eastern European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different Eastern European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different Eastern European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-eastern-european-markets-package-report.html>Medical Dressings - Eastern European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-eastern-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Western European Markets Package</title><link>http://www.researchmoz.com/medical-dressings-western-european-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-western-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-western-european-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different Western European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different Western European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different Western European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-western-european-markets-package-report.html>Medical Dressings - Western European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different Western European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different Western European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different Western European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-western-european-markets-package-report.html>Medical Dressings - Western European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-western-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - European Markets Package</title><link>http://www.researchmoz.com/medical-dressings-european-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-european-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-european-markets-package-report.html>Medical Dressings - European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-european-markets-package-report.html>Medical Dressings - European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Global Markets Package</title><link>http://www.researchmoz.com/medical-dressings-global-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-global-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-global-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different countries around the world. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different countries around the world?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 20 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-global-markets-package-report.html>Medical Dressings - Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in different countries around the world. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in different countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in different countries around the world?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 20 <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-global-markets-package-report.html>Medical Dressings - Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-global-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Top 10 Global Markets Package</title><link>http://www.researchmoz.com/medical-dressings-top-10-global-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-top-10-global-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-top-10-global-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in the top 10 global countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in top 10 global countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in top 10 global countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017

Countri <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-top-10-global-markets-package-report.html>Medical Dressings - Top 10 Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in the top 10 global countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in top 10 global countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in top 10 global countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017

Countri <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-top-10-global-markets-package-report.html>Medical Dressings - Top 10 Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-top-10-global-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Top 5 Asian Markets Package</title><link>http://www.researchmoz.com/medical-dressings-top-5-asian-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-top-5-asian-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-top-5-asian-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in the top 5 Asian countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in top 5 Asian countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in top 5 Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017

Countries inc <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-top-5-asian-markets-package-report.html>Medical Dressings - Top 5 Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in the top 5 Asian countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in top 5 Asian countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in top 5 Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017

Countries inc <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-top-5-asian-markets-package-report.html>Medical Dressings - Top 5 Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-top-5-asian-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Medical Dressings - Top 5 European Markets Package</title><link>http://www.researchmoz.com/medical-dressings-top-5-european-markets-package-report.html</link><comments>http://www.researchmoz.com/medical-dressings-top-5-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/medical-dressings-top-5-european-markets-package-report.html</guid><description><![CDATA[This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in the top 5 European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in top 5 European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in top 5 European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017

Countrie <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-top-5-european-markets-package-report.html>Medical Dressings - Top 5 European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This market research report package offers a perspective on the actual market situation, trends and future outlook for medical dressings in the top 5 European countries. The studies provide essential market information for decision-makers including:



Overall market for medical dressings in top 5 European countries
Market for medical dressings by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the medical dressing markets in top 5 European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Adhesive medical dressings
Other medical dressings



Years covered: 2006 2017

Countrie <br><br>Original Post <a href=http://www.researchmoz.com/medical-dressings-top-5-european-markets-package-report.html>Medical Dressings - Top 5 European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/medical-dressings-top-5-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - American Markets Package</title><link>http://www.researchmoz.com/vaccines-american-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-american-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-american-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different American countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different American countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different American countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Arge <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-american-markets-package-report.html>Vaccines - American Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different American countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different American countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different American countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Arge <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-american-markets-package-report.html>Vaccines - American Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-american-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - African Markets Package</title><link>http://www.researchmoz.com/vaccines-african-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-african-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-african-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different African countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different African countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different African countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Egypt,  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-african-markets-package-report.html>Vaccines - African Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different African countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different African countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different African countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Egypt,  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-african-markets-package-report.html>Vaccines - African Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-african-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Asian Markets Package</title><link>http://www.researchmoz.com/vaccines-asian-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-asian-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-asian-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Asian countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different Asian countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Armenia, Azer <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-asian-markets-package-report.html>Vaccines - Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Asian countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different Asian countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Armenia, Azer <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-asian-markets-package-report.html>Vaccines - Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-asian-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Eastern European Markets Package</title><link>http://www.researchmoz.com/vaccines-eastern-european-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-eastern-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-eastern-european-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Eastern European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different Eastern European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different Eastern European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-eastern-european-markets-package-report.html>Vaccines - Eastern European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Eastern European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different Eastern European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different Eastern European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-eastern-european-markets-package-report.html>Vaccines - Eastern European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-eastern-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Western European Markets Package</title><link>http://www.researchmoz.com/vaccines-western-european-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-western-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-western-european-markets-package-report.html</guid><description><![CDATA[This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Western European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different Western European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different Western European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-western-european-markets-package-report.html>Vaccines - Western European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different Western European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different Western European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different Western European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-western-european-markets-package-report.html>Vaccines - Western European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-western-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - European Markets Package</title><link>http://www.researchmoz.com/vaccines-european-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-european-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Aust <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-european-markets-package-report.html>Vaccines - European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Aust <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-european-markets-package-report.html>Vaccines - European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Global Markets Package</title><link>http://www.researchmoz.com/vaccines-global-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-global-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-global-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different countries around the world?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package: <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-global-markets-package-report.html>Vaccines - Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in different countries around the world. The studies provide essential market information for decision-makers including:



Overall market for vaccines in different countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in different countries around the world?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package: <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-global-markets-package-report.html>Vaccines - Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-global-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Top 10 Global Markets Package</title><link>http://www.researchmoz.com/vaccines-top-10-global-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-top-10-global-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-top-10-global-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in top 10 global countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in top 10 global countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

United States,  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-top-10-global-markets-package-report.html>Vaccines - Top 10 Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 10 global countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in top 10 global countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in top 10 global countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

United States,  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-top-10-global-markets-package-report.html>Vaccines - Top 10 Global Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-top-10-global-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Top 5 Asian Markets Package</title><link>http://www.researchmoz.com/vaccines-top-5-asian-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-top-5-asian-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-top-5-asian-markets-package-report.html</guid><description><![CDATA[This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 5 Asian countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in top 5 Asian countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in top 5 Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

China, India, Indonesia,  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-top-5-asian-markets-package-report.html>Vaccines - Top 5 Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 5 Asian countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in top 5 Asian countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in top 5 Asian countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

China, India, Indonesia,  <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-top-5-asian-markets-package-report.html>Vaccines - Top 5 Asian Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-top-5-asian-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Vaccines - Top 5 European Markets Package</title><link>http://www.researchmoz.com/vaccines-top-5-european-markets-package-report.html</link><comments>http://www.researchmoz.com/vaccines-top-5-european-markets-package-report.html#comments</comments><pubDate>Mon, 20 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/vaccines-top-5-european-markets-package-report.html</guid><description><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 5 European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in top 5 European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in top 5 European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Germany, Rus <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-top-5-european-markets-package-report.html>Vaccines - Top 5 European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

This market research report package offers a perspective on the actual market situation, trends and future outlook for vaccines in the top 5 European countries. The studies provide essential market information for decision-makers including:



Overall market for vaccines in top 5 European countries
Market for vaccines by product type
Forecasts and future outlook of the market
Macroeconomic indicators



These market studies answer to questions such as:



What is the size of the vaccine markets in top 5 European countries?
How are the markets divided into different types of products?&nbsp;
Which products are growing fast?
How the markets have been developing?&nbsp;
How does the future look like?
What is the potential for the markets?
How the macroeconomic indicators look like?&nbsp;



Product types discussed in the studies:



Human vaccines
Veterinary vaccines&nbsp;



Years covered: 2006 2017

Countries included in the package:

Germany, Rus <br><br>Original Post <a href=http://www.researchmoz.com/vaccines-top-5-european-markets-package-report.html>Vaccines - Top 5 European Markets Package</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/vaccines-top-5-european-markets-package-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France</title><link>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html</link><comments>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html</guid><description><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of France. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of France. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, france's population was approximately 65.3 million. The growth rate of the French population is decreasing steadily and this may be  <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape France. The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of France. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of France. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, france's population was approximately 65.3 million. The growth rate of the French population is decreasing steadily and this may be  <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - France</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-france-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy</title><link>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html</link><comments>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html</guid><description><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy. The report is an essential source of information and analysis on Italys healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and the countrys healthcare infrastructure. Most importantly, it provides valuable insights into the trends and segmentation of the Italian pharmaceutical and medical device markets. The report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

Italys population was 61.3 million in 2012, and is increasing due to a positive balance between the birth and death rates, as well as through immigratio <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy

Summary

GlobalData, the industry analysis specialist, has released its new report, CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Italy. The report is an essential source of information and analysis on Italys healthcare, regulatory and reimbursement landscape. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory and reimbursement landscape and the countrys healthcare infrastructure. Most importantly, it provides valuable insights into the trends and segmentation of the Italian pharmaceutical and medical device markets. The report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

Italys population was 61.3 million in 2012, and is increasing due to a positive balance between the birth and death rates, as well as through immigratio <br><br>Original Post <a href=http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html>CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Italy</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/countryfocus-healthcare-regulatory-and-reimbursement-landscape-italy-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players

Summary

GlobalData has released its pharma report, PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the competitive CML landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope



Investigation of current and future market competition for CML
Competitor assessment
Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
Strategic assessment of the CML sector through market impact analy <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players

Summary

GlobalData has released its pharma report, PharmaPoint: Chronic Myeloid Leukemia (CML) Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing CML Market. The report identifies and analyses the key companies shaping and driving the global CML market. The report provides insight into the competitive CML landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope



Investigation of current and future market competition for CML
Competitor assessment
Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
Strategic assessment of the CML sector through market impact analy <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Current and Future Players</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-current-and-future-players-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Novartis Gleevec (imatinib mesylate) was the first BCR-ABL TKI approved for CML. Gleevec was first approved in the US and the 5EU in 2001 for Ph+ CML patients in blast phase, accelerated ph <br><br>Original Post <a href=http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Gleevec (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Novartis Gleevec (imatinib mesylate) was the first BCR-ABL TKI approved for CML. Gleevec was first approved in the US and the 5EU in 2001 for Ph+ CML patients in blast phase, accelerated ph <br><br>Original Post <a href=http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Gleevec (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/gleevec-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, &ldquo;Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022&rdquo;. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients&rsquo; survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

BMS&rsquo; Sprycel (dasatinib) is a second-generation BCR-ABL TKI. Sprycel has a slightly different mechanism of action (MOA) than other TKIs used to treat CML, as it a <br><br>Original Post <a href=http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, &ldquo;Sprycel (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022&rdquo;. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients&rsquo; survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

BMS&rsquo; Sprycel (dasatinib) is a second-generation BCR-ABL TKI. Sprycel has a slightly different mechanism of action (MOA) than other TKIs used to treat CML, as it a <br><br>Original Post <a href=http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Sprycel (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sprycel-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Novartis Tasigna (nilotinib) is a second-generation BCR-ABL TKI. It was first approved in the US and 5EU in 2007 and in Japan in 2009 as a second-line therapy for patients with CP or AP CML that  <br><br>Original Post <a href=http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Tasigna (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Novartis Tasigna (nilotinib) is a second-generation BCR-ABL TKI. It was first approved in the US and 5EU in 2007 and in Japan in 2009 as a second-line therapy for patients with CP or AP CML that  <br><br>Original Post <a href=http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Tasigna (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/tasigna-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Pfizers Bosulif (bosutinib) is a second-generation TKI that inhibits BCR-ABL, as well as SRC-family kinases (Bosulif Prescribing Information, 2012). Bosulif received FDA approval in Septemb <br><br>Original Post <a href=http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Bosulif (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Pfizers Bosulif (bosutinib) is a second-generation TKI that inhibits BCR-ABL, as well as SRC-family kinases (Bosulif Prescribing Information, 2012). Bosulif received FDA approval in Septemb <br><br>Original Post <a href=http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Bosulif (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bosulif-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Ariads Iclusig (ponatinib) is an orally administered, third-generation TKI that inhibits the activity of wild-type ABL and T315I mutant ABL in vitro. Iclusig has received orphan drug design <br><br>Original Post <a href=http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Iclusig (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.&nbsp;

Ariads Iclusig (ponatinib) is an orally administered, third-generation TKI that inhibits the activity of wild-type ABL and T315I mutant ABL in vitro. Iclusig has received orphan drug design <br><br>Original Post <a href=http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Iclusig (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/iclusig-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Tevas Synribo (omacetaxine mepesuccinate) is a chemotherapy for the treatment of CP or AP CML that is resistant to prior therapy with multiple TKIs. Synribo was originally developed by ChemGenex, <br><br>Original Post <a href=http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Synribo (Chronic Myeloid Leukemia) Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Tevas Synribo (omacetaxine mepesuccinate) is a chemotherapy for the treatment of CP or AP CML that is resistant to prior therapy with multiple TKIs. Synribo was originally developed by ChemGenex, <br><br>Original Post <a href=http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html>Synribo (Chronic Myeloid Leukemia) - Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/synribo-chronic-myeloid-leukemia-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022</title><link>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html</link><comments>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html</guid><description><![CDATA[

EpiCast Report: Meningococcal Disease Epidemiology Forecast to 2022

Summary

Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplet <br><br>Original Post <a href=http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html>EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

EpiCast Report: Meningococcal Disease Epidemiology Forecast to 2022

Summary

Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplet <br><br>Original Post <a href=http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html>EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals</title><link>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html</link><comments>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html#comments</comments><pubDate>Wed, 15 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html</guid><description><![CDATA[

Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&amp;As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&amp;As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database  <br><br>Original Post <a href=http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html>Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals

Summary

GlobalData's Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&amp;As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&amp;As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in April 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house deals database  <br><br>Original Post <a href=http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html>Partnerships, Licensing, Investments and M&amp;A Deals and Trends for April 2013 in Pharmaceuticals</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-for-april-2013-in-pharmaceuticals-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>China Denture Industry 2013 Deep Research Report</title><link>http://www.researchmoz.com/china-denture-industry-2013-deep-research-report-report.html</link><comments>http://www.researchmoz.com/china-denture-industry-2013-deep-research-report-report.html#comments</comments><pubDate>Tue, 14 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/china-denture-industry-2013-deep-research-report-report.html</guid><description><![CDATA[Summary

2013 Deep Research Report on China Denture Industry was professional and depth research report on China Denture &nbsp; industry.&nbsp;

The report firstly introduced Denture basic information included Denture &nbsp; definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Denture &nbsp;industry policy and plan, Denture &nbsp;product specification, manufacturing process, product cost structure etc. then statistics China key manufacturers Denture &nbsp;capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Denture products customers application capacity market position company contact information etc company related information, then collect all these manufacturers data and listed China Denture &nbsp; capacity production capacity m <br><br>Original Post <a href=http://www.researchmoz.com/china-denture-industry-2013-deep-research-report-report.html>China Denture Industry 2013 Deep Research Report</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Summary

2013 Deep Research Report on China Denture Industry was professional and depth research report on China Denture &nbsp; industry.&nbsp;

The report firstly introduced Denture basic information included Denture &nbsp; definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Denture &nbsp;industry policy and plan, Denture &nbsp;product specification, manufacturing process, product cost structure etc. then statistics China key manufacturers Denture &nbsp;capacity production cost price profit production value gross margin etc details information, at the same time, statistics these manufacturers Denture products customers application capacity market position company contact information etc company related information, then collect all these manufacturers data and listed China Denture &nbsp; capacity production capacity m <br><br>Original Post <a href=http://www.researchmoz.com/china-denture-industry-2013-deep-research-report-report.html>China Denture Industry 2013 Deep Research Report</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/china-denture-industry-2013-deep-research-report-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth</title><link>http://www.researchmoz.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-report.html</link><comments>http://www.researchmoz.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-report.html#comments</comments><pubDate>Tue, 14 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-report.html</guid><description><![CDATA[

The leading business intelligence provider GBI Research has released its latest research report, entitled &ldquo;Travel Vaccines Market to 2019 &ndash; Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth&rdquo;. The report provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&amp;D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market.&nbsp;

The report analyzes the market for Travel Vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. In addition, it provides overview of vaccines market in India, China and Australia including regulatory frameworks and profiles of the top companies, deals and pipeline analysis. The report discusses the global pipeline for Travel <br><br>Original Post <a href=http://www.researchmoz.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-report.html>Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The leading business intelligence provider GBI Research has released its latest research report, entitled &ldquo;Travel Vaccines Market to 2019 &ndash; Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth&rdquo;. The report provides insights into the vaccines in the Travel Vaccines market including market forecasts up to 2019. It provides an in-depth analysis of the travel vaccines, as well as insights into the Travel Vaccines R&amp;D pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the global Travel Vaccines market.&nbsp;

The report analyzes the market for Travel Vaccines in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. In addition, it provides overview of vaccines market in India, China and Australia including regulatory frameworks and profiles of the top companies, deals and pipeline analysis. The report discusses the global pipeline for Travel <br><br>Original Post <a href=http://www.researchmoz.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-report.html>Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/travel-vaccines-market-to-2019-hepatitis-a-japanese-encephalitis-and-meningococcal-vaccine-segments-to-drive-growth-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific</title><link>http://www.researchmoz.com/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific-report.html</link><comments>http://www.researchmoz.com/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific-report.html#comments</comments><pubDate>Tue, 14 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific-report.html</guid><description><![CDATA[

GBI Research, the leading business intelligence provider, has released its latest research, &ldquo;Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific&rdquo;. The report provides in-depth analysis of the drivers and barriers that affect the global critical care market. The report has been compiled using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research&rsquo;s team of industry experts.&nbsp;

The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia. The report provides an overview of major marketed products in critical care ma <br><br>Original Post <a href=http://www.researchmoz.com/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific-report.html>Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

GBI Research, the leading business intelligence provider, has released its latest research, &ldquo;Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific&rdquo;. The report provides in-depth analysis of the drivers and barriers that affect the global critical care market. The report has been compiled using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research&rsquo;s team of industry experts.&nbsp;

The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan. The report does also provide an overview on Asia-Pacific countries, including China, India and Australia. The report provides an overview of major marketed products in critical care ma <br><br>Original Post <a href=http://www.researchmoz.com/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific-report.html>Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/critical-care-market-to-2019-growth-from-factor-concentrates-new-indications-and-increasing-demand-for-albumin-in-asia-pacific-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>South Korea Pharmaceutical Market Outlook 2013</title><link>http://www.researchmoz.com/south-korea-pharmaceutical-market-outlook-2013-report.html</link><comments>http://www.researchmoz.com/south-korea-pharmaceutical-market-outlook-2013-report.html#comments</comments><pubDate>Tue, 14 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/south-korea-pharmaceutical-market-outlook-2013-report.html</guid><description><![CDATA[
South Korea Pharmaceutical Market Outlook 2013

Summary

GBI Research&rsquo;s new report &ldquo;South Korea Pharmaceutical Market Outlook 2013&rdquo; provides in-depth analysis of the trends, issues and challenges facing the South Korean pharmaceutical market. The report also provides competitive benchmarking for the country&rsquo;s leading pharmaceutical companies and analyzes the M&amp;A (Mergers and Acquisitions) and strategic partnerships that shape its pharmaceutical industry. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research&rsquo;s team of industry experts.

The South Korean pharmaceutical market is the 10th largest pharmaceutical market, globally. The industry is highly fragmented, with almost all the domestic pharmaceutical companies having a strong portfolio of generic products rather than expensive, branded drugs. For the entire pharmaceutical industry, an increase in insura <br><br>Original Post <a href=http://www.researchmoz.com/south-korea-pharmaceutical-market-outlook-2013-report.html>South Korea Pharmaceutical Market Outlook 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
South Korea Pharmaceutical Market Outlook 2013

Summary

GBI Research&rsquo;s new report &ldquo;South Korea Pharmaceutical Market Outlook 2013&rdquo; provides in-depth analysis of the trends, issues and challenges facing the South Korean pharmaceutical market. The report also provides competitive benchmarking for the country&rsquo;s leading pharmaceutical companies and analyzes the M&amp;A (Mergers and Acquisitions) and strategic partnerships that shape its pharmaceutical industry. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research&rsquo;s team of industry experts.

The South Korean pharmaceutical market is the 10th largest pharmaceutical market, globally. The industry is highly fragmented, with almost all the domestic pharmaceutical companies having a strong portfolio of generic products rather than expensive, branded drugs. For the entire pharmaceutical industry, an increase in insura <br><br>Original Post <a href=http://www.researchmoz.com/south-korea-pharmaceutical-market-outlook-2013-report.html>South Korea Pharmaceutical Market Outlook 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/south-korea-pharmaceutical-market-outlook-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Video Conferencing Market in Healthcare Industry 2012-2016</title><link>http://www.researchmoz.com/global-video-conferencing-market-in-healthcare-industry-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-video-conferencing-market-in-healthcare-industry-2012-2016-report.html#comments</comments><pubDate>Fri, 10 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-video-conferencing-market-in-healthcare-industry-2012-2016-report.html</guid><description><![CDATA[
Description:&nbsp;

TechNavio's analysts forecast the Global Video Conferencing Market in Healthcare Industry to grow at a CAGR of 18.06 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need to access healthcare facilities in rural areas. The Global Video Conferencing Market in Healthcare Industry has also been witnessing availability of cloud-based services. However, the issues concerning quality of health information could pose a challenge to the growth of this market.

TechNavio's report, the Global Video Conferencing Market in Healthcare Industry 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Video Conferencing Market in Healthcare Industry landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key v <br><br>Original Post <a href=http://www.researchmoz.com/global-video-conferencing-market-in-healthcare-industry-2012-2016-report.html>Global Video Conferencing Market in Healthcare Industry 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Description:&nbsp;

TechNavio's analysts forecast the Global Video Conferencing Market in Healthcare Industry to grow at a CAGR of 18.06 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need to access healthcare facilities in rural areas. The Global Video Conferencing Market in Healthcare Industry has also been witnessing availability of cloud-based services. However, the issues concerning quality of health information could pose a challenge to the growth of this market.

TechNavio's report, the Global Video Conferencing Market in Healthcare Industry 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Video Conferencing Market in Healthcare Industry landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key v <br><br>Original Post <a href=http://www.researchmoz.com/global-video-conferencing-market-in-healthcare-industry-2012-2016-report.html>Global Video Conferencing Market in Healthcare Industry 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-video-conferencing-market-in-healthcare-industry-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Analysis of the perfume&amp;cosmetic retail market in Russia - in English and Russian languages</title><link>http://www.researchmoz.com/analysis-of-the-perfumeandcosmetic-retail-market-in-russia-in-english-and-russian-languages-report.html</link><comments>http://www.researchmoz.com/analysis-of-the-perfumeandcosmetic-retail-market-in-russia-in-english-and-russian-languages-report.html#comments</comments><pubDate>Fri, 10 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/analysis-of-the-perfumeandcosmetic-retail-market-in-russia-in-english-and-russian-languages-report.html</guid><description><![CDATA[

Purpose of this report was to analyse the perfume &amp; cosmetic retail industry in Russia.

Please pay attention:

Benefits of buying the report:



The report provides information, which gives very good understanding of trends and dynamics of the market in Russia.
The report forms a view with respect to development of the market. This view and forecast can be used in running scenario analysis to build financial models, investment analysis and strategy formulation.
Main competitors were analyzed during the course of the report. You will get clear understanding of level of competition in Russia.



This report saves lots of time.&nbsp;

According to our estimates the report saves more than a month in analyst time of search and analysis of industry information and data.
This time can be used more efficiently.


If you need to get quick understanding of the market than this product is a very good tool to get it done efficiently from the quality/price point of view <br><br>Original Post <a href=http://www.researchmoz.com/analysis-of-the-perfumeandcosmetic-retail-market-in-russia-in-english-and-russian-languages-report.html>Analysis of the perfume&amp;cosmetic retail market in Russia - in English and Russian languages</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Purpose of this report was to analyse the perfume &amp; cosmetic retail industry in Russia.

Please pay attention:

Benefits of buying the report:



The report provides information, which gives very good understanding of trends and dynamics of the market in Russia.
The report forms a view with respect to development of the market. This view and forecast can be used in running scenario analysis to build financial models, investment analysis and strategy formulation.
Main competitors were analyzed during the course of the report. You will get clear understanding of level of competition in Russia.



This report saves lots of time.&nbsp;

According to our estimates the report saves more than a month in analyst time of search and analysis of industry information and data.
This time can be used more efficiently.


If you need to get quick understanding of the market than this product is a very good tool to get it done efficiently from the quality/price point of view <br><br>Original Post <a href=http://www.researchmoz.com/analysis-of-the-perfumeandcosmetic-retail-market-in-russia-in-english-and-russian-languages-report.html>Analysis of the perfume&amp;cosmetic retail market in Russia - in English and Russian languages</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/analysis-of-the-perfumeandcosmetic-retail-market-in-russia-in-english-and-russian-languages-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Russian pharma industry in details - in English and Russian languages</title><link>http://www.researchmoz.com/russian-pharma-industry-in-details-in-english-and-russian-languages-report.html</link><comments>http://www.researchmoz.com/russian-pharma-industry-in-details-in-english-and-russian-languages-report.html#comments</comments><pubDate>Thu, 09 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/russian-pharma-industry-in-details-in-english-and-russian-languages-report.html</guid><description><![CDATA[

Purpose of this report was to analyze Russian of pharma.

Please pay attention:

Benefits of buying the report:



The report included large volume of information on Russian pharma industry. The report is ready to be used for presentations, research reports and strategies. The report could also be used in preparation of marketing materials.
The focus of the report &ndash; development of pharma market in Russia. The report contains information on pharma clusters in regions of Russia.
The report has information on regulation of the pharma industry in Russia. In one report you will get references on norms, regulating pharma industry in Russia.
The report provides information, which gives very good understanding of trends and dynamics of the market in Russia.
The report forms a view with respect to development of the market. This view and forecast can be used in running scenario analysis to build financial models, investment analysis and strategy formulation.
Main competit <br><br>Original Post <a href=http://www.researchmoz.com/russian-pharma-industry-in-details-in-english-and-russian-languages-report.html>Russian pharma industry in details - in English and Russian languages</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Purpose of this report was to analyze Russian of pharma.

Please pay attention:

Benefits of buying the report:



The report included large volume of information on Russian pharma industry. The report is ready to be used for presentations, research reports and strategies. The report could also be used in preparation of marketing materials.
The focus of the report &ndash; development of pharma market in Russia. The report contains information on pharma clusters in regions of Russia.
The report has information on regulation of the pharma industry in Russia. In one report you will get references on norms, regulating pharma industry in Russia.
The report provides information, which gives very good understanding of trends and dynamics of the market in Russia.
The report forms a view with respect to development of the market. This view and forecast can be used in running scenario analysis to build financial models, investment analysis and strategy formulation.
Main competit <br><br>Original Post <a href=http://www.researchmoz.com/russian-pharma-industry-in-details-in-english-and-russian-languages-report.html>Russian pharma industry in details - in English and Russian languages</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/russian-pharma-industry-in-details-in-english-and-russian-languages-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pharmacy Retail Market in India 2013</title><link>http://www.researchmoz.com/pharmacy-retail-market-in-india-2013-report.html</link><comments>http://www.researchmoz.com/pharmacy-retail-market-in-india-2013-report.html#comments</comments><pubDate>Wed, 08 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmacy-retail-market-in-india-2013-report.html</guid><description><![CDATA[
The new report, Pharmacy Retail Market in India, elaborates the changing role of pharmacy outlets and the gradual progression it is seeing towards building an organized format. The market is sustainable and is projected towards significant growth due to the already existing varied disease profile as well as the emerging new diseases and the growing population size being affected by such diseases.

The pharmacy sector forms the second largest share in the Indian healthcare sector. The sector sources its products through institutional and non institutional sales. The institutional sales is the sale of pharmaceuticals to hospitals, nursing homes and other such health institutions that purchase bulk drugs at discounted prices that results in partial decline in profit margin of manufacturers. Whereas, non institutional sales takes place through retail stores that happen to be the only form of sales channel that reaches directly to consumers and is a major source of revenue earning for t <br><br>Original Post <a href=http://www.researchmoz.com/pharmacy-retail-market-in-india-2013-report.html>Pharmacy Retail Market in India 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
The new report, Pharmacy Retail Market in India, elaborates the changing role of pharmacy outlets and the gradual progression it is seeing towards building an organized format. The market is sustainable and is projected towards significant growth due to the already existing varied disease profile as well as the emerging new diseases and the growing population size being affected by such diseases.

The pharmacy sector forms the second largest share in the Indian healthcare sector. The sector sources its products through institutional and non institutional sales. The institutional sales is the sale of pharmaceuticals to hospitals, nursing homes and other such health institutions that purchase bulk drugs at discounted prices that results in partial decline in profit margin of manufacturers. Whereas, non institutional sales takes place through retail stores that happen to be the only form of sales channel that reaches directly to consumers and is a major source of revenue earning for t <br><br>Original Post <a href=http://www.researchmoz.com/pharmacy-retail-market-in-india-2013-report.html>Pharmacy Retail Market in India 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmacy-retail-market-in-india-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease</title><link>http://www.researchmoz.com/immunoglobulins-market-to-2019-demand-in-primary-immunodeficiency-pi-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-potentially-supplemented-by-approvals-for-alzheimers-disease-report.html</link><comments>http://www.researchmoz.com/immunoglobulins-market-to-2019-demand-in-primary-immunodeficiency-pi-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-potentially-supplemented-by-approvals-for-alzheimers-disease-report.html#comments</comments><pubDate>Fri, 03 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/immunoglobulins-market-to-2019-demand-in-primary-immunodeficiency-pi-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-potentially-supplemented-by-approvals-for-alzheimers-disease-report.html</guid><description><![CDATA[

GBI Research&rsquo;s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.&nbsp;

The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barr&eacute; Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.&nbsp;


The report has been built using data and information sourced from proprieta <br><br>Original Post <a href=http://www.researchmoz.com/immunoglobulins-market-to-2019-demand-in-primary-immunodeficiency-pi-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-potentially-supplemented-by-approvals-for-alzheimers-disease-report.html>Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

GBI Research&rsquo;s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.&nbsp;

The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barr&eacute; Syndrome (GBS), Myasthenia Gravis (MG), Idiopathic Thrombocytopenic Purpura (ITP), and Chronic Lymphocytic Leukemia (CLL). The report also profiles the marketed products, key pipeline products, and leading companies that could change the market landscape in the forecast period.&nbsp;


The report has been built using data and information sourced from proprieta <br><br>Original Post <a href=http://www.researchmoz.com/immunoglobulins-market-to-2019-demand-in-primary-immunodeficiency-pi-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-potentially-supplemented-by-approvals-for-alzheimers-disease-report.html>Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/immunoglobulins-market-to-2019-demand-in-primary-immunodeficiency-pi-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-potentially-supplemented-by-approvals-for-alzheimers-disease-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Discovery Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</link><comments>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</guid><description><![CDATA[

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contr <br><br>Original Post <a href=http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered &ndash; contr <br><br>Original Post <a href=http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/discovery-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cancer Monoclonal Antibody Partnering Terms and Agreements</title><link>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html</guid><description><![CDATA[

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value


The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody techn <br><br>Original Post <a href=http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html>Cancer Monoclonal Antibody Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer monoclonal antibody partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer monoclonal antibody partnering contract documents
Top cancer monoclonal antibody deals by value


The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer monoclonal antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors monoclonal antibody techn <br><br>Original Post <a href=http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html>Cancer Monoclonal Antibody Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cancer-monoclonal-antibody-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cancer Vaccine Partnering Terms and Agreements</title><link>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html</link><comments>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html</guid><description><![CDATA[

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value


&nbsp;
The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercializa <br><br>Original Post <a href=http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html>Cancer Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in cancer vaccine partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Cancer vaccine partnering contract documents
Top cancer vaccine deals by value


&nbsp;
The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercializa <br><br>Original Post <a href=http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html>Cancer Vaccine Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cancer-vaccine-partnering-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters &amp; Biosuperiors</title><link>http://www.researchmoz.com/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors-report.html</link><comments>http://www.researchmoz.com/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors-report.html</guid><description><![CDATA[Competitor Analysis: Therapeutic Proteins &ndash; Biosimilars, Biobetters &amp; Biosuperiors

The new Competitive Intelligence Report Therapeutic Proteins &ndash; Biosimilars, Biobetters &amp; Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:



Erythropoietin (EPO) &amp; Erythropoiesis Stimulating Agents (ESA)
G-CSF &amp; GM-CSF
Thrombopoietin &amp; Thrombopoiesis Stimulating Agents
Interferon
Insulin
Coagulation Factors
Human Growth Hormone (hGH)
FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)
Thrombolytics &amp; Fibrinolytics
Enzyme Replacement Therapies


Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Austral <br><br>Original Post <a href=http://www.researchmoz.com/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors-report.html>Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters &amp; Biosuperiors</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Competitor Analysis: Therapeutic Proteins &ndash; Biosimilars, Biobetters &amp; Biosuperiors

The new Competitive Intelligence Report Therapeutic Proteins &ndash; Biosimilars, Biobetters &amp; Biosuperiors of May 2013 provides a competitor analysis in the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and biobetter/biosuperior versions in regulated and less regulated markets:



Erythropoietin (EPO) &amp; Erythropoiesis Stimulating Agents (ESA)
G-CSF &amp; GM-CSF
Thrombopoietin &amp; Thrombopoiesis Stimulating Agents
Interferon
Insulin
Coagulation Factors
Human Growth Hormone (hGH)
FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)
Thrombolytics &amp; Fibrinolytics
Enzyme Replacement Therapies


Territories covered are the major pharmaceutical markets North America, Europe and Japan, as well as South Korea, India, China and other countries in Latin America, Africa and Austral <br><br>Original Post <a href=http://www.researchmoz.com/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors-report.html>Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters &amp; Biosuperiors</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</link><comments>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</guid><description><![CDATA[

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.&nbsp;
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are <br><br>Original Post <a href=http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.&nbsp;
&nbsp;
Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are <br><br>Original Post <a href=http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/preclinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Antibiotics Partnering Terms and Agreements</title><link>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html</link><comments>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html</guid><description><![CDATA[

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value


The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commerci <br><br>Original Post <a href=http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html>Antibiotics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;


Trends in antibiotics partnering deals
Disclosed headlines, upfronts, milestones and royalties by stage of development
Antibiotics partnering contract documents
Top antibiotics deals by value


The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
&nbsp;
The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commerci <br><br>Original Post <a href=http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html>Antibiotics Partnering Terms and Agreements</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/antibiotics-partnering-terms-and-agreements-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</title><link>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</link><comments>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html</guid><description><![CDATA[

Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies&nbsp;

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical  <br><br>Original Post <a href=http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies&nbsp;

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&amp;D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner&rsquo;s negotiated deals terms provides critical  <br><br>Original Post <a href=http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html>Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/discovery-preclinical-and-clinical-stage-partnering-terms-and-agreements-in-pharma-and-biotech-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Antibiotics Markets in China</title><link>http://www.researchmoz.com/antibiotics-markets-in-china-report.html</link><comments>http://www.researchmoz.com/antibiotics-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/antibiotics-markets-in-china-report.html</guid><description><![CDATA[China's demand for antibiotics has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/antibiotics-markets-in-china-report.html>Antibiotics Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for antibiotics has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/antibiotics-markets-in-china-report.html>Antibiotics Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/antibiotics-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Autoimmune Drugs Markets in China</title><link>http://www.researchmoz.com/autoimmune-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/autoimmune-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/autoimmune-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for autoimmune drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/autoimmune-drugs-markets-in-china-report.html>Autoimmune Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for autoimmune drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/autoimmune-drugs-markets-in-china-report.html>Autoimmune Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/autoimmune-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Blood Disease Treatment Drugs Markets in China</title><link>http://www.researchmoz.com/blood-disease-treatment-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/blood-disease-treatment-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/blood-disease-treatment-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for blood treatment disease drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/blood-disease-treatment-drugs-markets-in-china-report.html>Blood Disease Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for blood treatment disease drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/blood-disease-treatment-drugs-markets-in-china-report.html>Blood Disease Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/blood-disease-treatment-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hypertension Treatment Drugs Markets in China</title><link>http://www.researchmoz.com/hypertension-treatment-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/hypertension-treatment-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hypertension-treatment-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for hypertension treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/hypertension-treatment-drugs-markets-in-china-report.html>Hypertension Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for hypertension treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/hypertension-treatment-drugs-markets-in-china-report.html>Hypertension Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hypertension-treatment-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Mental Illness Treatment Drugs Markets in China</title><link>http://www.researchmoz.com/mental-illness-treatment-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/mental-illness-treatment-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mental-illness-treatment-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for mental illness treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/mental-illness-treatment-drugs-markets-in-china-report.html>Mental Illness Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for mental illness treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/mental-illness-treatment-drugs-markets-in-china-report.html>Mental Illness Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mental-illness-treatment-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Anti-Obesity Drugs Markets in China</title><link>http://www.researchmoz.com/anti-obesity-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/anti-obesity-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/anti-obesity-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for anti-obesity drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/anti-obesity-drugs-markets-in-china-report.html>Anti-Obesity Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for anti-obesity drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/anti-obesity-drugs-markets-in-china-report.html>Anti-Obesity Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/anti-obesity-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Osteoporosis Treatment Drugs  Markets in China</title><link>http://www.researchmoz.com/osteoporosis-treatment-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/osteoporosis-treatment-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/osteoporosis-treatment-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for osteoporosis treatment drugs  has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/osteoporosis-treatment-drugs-markets-in-china-report.html>Osteoporosis Treatment Drugs  Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for osteoporosis treatment drugs  has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/osteoporosis-treatment-drugs-markets-in-china-report.html>Osteoporosis Treatment Drugs  Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/osteoporosis-treatment-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Anti-Tumor Drugs Markets in China</title><link>http://www.researchmoz.com/anti-tumor-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/anti-tumor-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/anti-tumor-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for anti-tumor drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/anti-tumor-drugs-markets-in-china-report.html>Anti-Tumor Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for anti-tumor drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/anti-tumor-drugs-markets-in-china-report.html>Anti-Tumor Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/anti-tumor-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Lymphoma Treatment Drugs Markets in China</title><link>http://www.researchmoz.com/lymphoma-treatment-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/lymphoma-treatment-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/lymphoma-treatment-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for lymphoma treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/lymphoma-treatment-drugs-markets-in-china-report.html>Lymphoma Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for lymphoma treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/lymphoma-treatment-drugs-markets-in-china-report.html>Lymphoma Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/lymphoma-treatment-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Central Nervous System Disorder Drugs Markets in China</title><link>http://www.researchmoz.com/central-nervous-system-disorder-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/central-nervous-system-disorder-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/central-nervous-system-disorder-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for central nervous system disorder drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/central-nervous-system-disorder-drugs-markets-in-china-report.html>Central Nervous System Disorder Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for central nervous system disorder drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/central-nervous-system-disorder-drugs-markets-in-china-report.html>Central Nervous System Disorder Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/central-nervous-system-disorder-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Monoclonal Antibody Markets in China</title><link>http://www.researchmoz.com/monoclonal-antibody-markets-in-china-report.html</link><comments>http://www.researchmoz.com/monoclonal-antibody-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/monoclonal-antibody-markets-in-china-report.html</guid><description><![CDATA[China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/monoclonal-antibody-markets-in-china-report.html>Monoclonal Antibody Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/monoclonal-antibody-markets-in-china-report.html>Monoclonal Antibody Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/monoclonal-antibody-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Smoking Cessation Aids Markets in China</title><link>http://www.researchmoz.com/smoking-cessation-aids-markets-in-china-report.html</link><comments>http://www.researchmoz.com/smoking-cessation-aids-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/smoking-cessation-aids-markets-in-china-report.html</guid><description><![CDATA[China's demand for smoking cessation aids has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/smoking-cessation-aids-markets-in-china-report.html>Smoking Cessation Aids Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for smoking cessation aids has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/smoking-cessation-aids-markets-in-china-report.html>Smoking Cessation Aids Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/smoking-cessation-aids-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Disinfectants Markets in China</title><link>http://www.researchmoz.com/disinfectants-markets-in-china-report.html</link><comments>http://www.researchmoz.com/disinfectants-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/disinfectants-markets-in-china-report.html</guid><description><![CDATA[China's demand for disinfectants has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/disinfectants-markets-in-china-report.html>Disinfectants Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for disinfectants has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/disinfectants-markets-in-china-report.html>Disinfectants Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/disinfectants-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pneumonia Treatment Drugs Markets in China</title><link>http://www.researchmoz.com/pneumonia-treatment-drugs-markets-in-china-report.html</link><comments>http://www.researchmoz.com/pneumonia-treatment-drugs-markets-in-china-report.html#comments</comments><pubDate>Wed, 01 May 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pneumonia-treatment-drugs-markets-in-china-report.html</guid><description><![CDATA[China's demand for pneumonia treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/pneumonia-treatment-drugs-markets-in-china-report.html>Pneumonia Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[China's demand for pneumonia treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled. <br><br>Original Post <a href=http://www.researchmoz.com/pneumonia-treatment-drugs-markets-in-china-report.html>Pneumonia Treatment Drugs Markets in China</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pneumonia-treatment-drugs-markets-in-china-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals  Q1 2013</title><link>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2013-report.html</link><comments>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2013-report.html</guid><description><![CDATA[

Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals Q1 2013

Summary

GlobalData's Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals Q1 2013 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&amp;A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&amp;As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q1 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in- <br><br>Original Post <a href=http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2013-report.html>Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals  Q1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals Q1 2013

Summary

GlobalData's Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals Q1 2013 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&amp;A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&amp;As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q1 2013. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry.

GlobalData derived the data presented in this report from proprietary in- <br><br>Original Post <a href=http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2013-report.html>Partnerships, Licensing, Investments and M&amp;A Deals and Trends in Pharmaceuticals  Q1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/partnerships-licensing-investments-and-manda-deals-and-trends-in-pharmaceuticals-q1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan</title><link>http://www.researchmoz.com/generic-and-innovative-drugs-market-in-cis-countries-2013-russia-ukraine-and-kazakhstan-report.html</link><comments>http://www.researchmoz.com/generic-and-innovative-drugs-market-in-cis-countries-2013-russia-ukraine-and-kazakhstan-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/generic-and-innovative-drugs-market-in-cis-countries-2013-russia-ukraine-and-kazakhstan-report.html</guid><description><![CDATA[Keep current with the changing CIS generic and innovative drug segments.
Survey conditions and track market development in Russian Ukraine and Kazakhstan to 2015.
Generic and innovative drug segments in CIS countries have played a huge role in 
supporting the pharmaceutical industry. Meanwhile, the effects of programmes such as Russias Pharma 2020, Kazakhstans GMP initiative and Ukraines updated reimbursement structure are visible in the marketplace.&nbsp;
How will issues like these influence market development in the next few years? How will they change pricing structures and reimbursement schemes? What are the rules regarding data exclusivity periods and drug patent viability?
Stay informed with regard to these topics and many more by reviewing Generic and innovative drugs market in CIS countries 2013, Russia, Ukraine and Kazakhstan, Development forecasts for 2013-2015. This authoritative report is a single and complete source of market data, analysis and forecasts, combined to  <br><br>Original Post <a href=http://www.researchmoz.com/generic-and-innovative-drugs-market-in-cis-countries-2013-russia-ukraine-and-kazakhstan-report.html>Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Keep current with the changing CIS generic and innovative drug segments.
Survey conditions and track market development in Russian Ukraine and Kazakhstan to 2015.
Generic and innovative drug segments in CIS countries have played a huge role in 
supporting the pharmaceutical industry. Meanwhile, the effects of programmes such as Russias Pharma 2020, Kazakhstans GMP initiative and Ukraines updated reimbursement structure are visible in the marketplace.&nbsp;
How will issues like these influence market development in the next few years? How will they change pricing structures and reimbursement schemes? What are the rules regarding data exclusivity periods and drug patent viability?
Stay informed with regard to these topics and many more by reviewing Generic and innovative drugs market in CIS countries 2013, Russia, Ukraine and Kazakhstan, Development forecasts for 2013-2015. This authoritative report is a single and complete source of market data, analysis and forecasts, combined to  <br><br>Original Post <a href=http://www.researchmoz.com/generic-and-innovative-drugs-market-in-cis-countries-2013-russia-ukraine-and-kazakhstan-report.html>Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/generic-and-innovative-drugs-market-in-cis-countries-2013-russia-ukraine-and-kazakhstan-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-states-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-states-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-states-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) United States Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) United States Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

This decline will be driven by the launch of generic imatinib in 2015 and generic dasatinib in 2020; the increased uptake of higher-priced therapies like Bosuli <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-states-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) United States Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) United States Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

This decline will be driven by the launch of generic imatinib in 2015 and generic dasatinib in 2020; the increased uptake of higher-priced therapies like Bosuli <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-states-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-states-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-france-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-france-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-france-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) France Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) France Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

The decrease in size of the overall market will be driven by generic erosion of Gleevec and Sprycel sales following their expected patent expiries in 2016 and 2020. Sales of  <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-france-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) France Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) France Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

The decrease in size of the overall market will be driven by generic erosion of Gleevec and Sprycel sales following their expected patent expiries in 2016 and 2020. Sales of  <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-france-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - France Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-france-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-germany-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-germany-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-germany-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Germany Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Germany Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

After it enters the market in 2016, generic imatinib will displace Gleevec as the most commonly prescribed first-line therapy for CP-CML patients. Historically, the German <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-germany-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Germany Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Germany Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

After it enters the market in 2016, generic imatinib will displace Gleevec as the most commonly prescribed first-line therapy for CP-CML patients. Historically, the German <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-germany-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Germany Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-germany-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-italy-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-italy-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-italy-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Italy Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Italy Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Italy has not historically been a major generics market, but the current economic crisis will necessitate rapid transition from branded to generic drugs once they become avail <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-italy-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Italy Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Italy Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Italy has not historically been a major generics market, but the current economic crisis will necessitate rapid transition from branded to generic drugs once they become avail <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-italy-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Italy Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-italy-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-spain-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-spain-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-spain-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Spain Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Spain Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Spain has the lowest prevalence of CML of the 7MM, and is the second-smallest CML market. Any drivers of market growth, including the launch of Bosulif and Iclusig and an incr <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-spain-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Spain Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Spain Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Spain has the lowest prevalence of CML of the 7MM, and is the second-smallest CML market. Any drivers of market growth, including the launch of Bosulif and Iclusig and an incr <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-spain-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Spain Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-spain-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[


PharmaPoint: Chronic Myeloid Leukemia (CML) United Kingdom Drug Forecast and Market Analysis to 2022


Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) United Kingdom Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

The UK has the second lowest prevalence of CML, and is currently the smallest CML market of the 7MM. Although an increasing prevalence of CML and the laun <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[


PharmaPoint: Chronic Myeloid Leukemia (CML) United Kingdom Drug Forecast and Market Analysis to 2022


Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) United Kingdom Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems

The UK has the second lowest prevalence of CML, and is currently the smallest CML market of the 7MM. Although an increasing prevalence of CML and the laun <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-united-kingdom-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022</title><link>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-japan-drug-forecast-and-market-analysis-to-2022-report.html</link><comments>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-japan-drug-forecast-and-market-analysis-to-2022-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-japan-drug-forecast-and-market-analysis-to-2022-report.html</guid><description><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Japan is the second-largest CML market of the 7MM, due to a high prevalence of CML, exceptionally high drug treatment rates and rapid uptake of premium-priced second-generatio <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-japan-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaPoint: Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, PharmaPoint: Chronic Myeloid Leukemia (CML) Japan Drug Forecast and Market Analysis to 2022. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL fusion protein. The stage of CML is classified as chronic, accelerated or blast phase, ranging from least to most severe. Multiple BCR-ABL tyrosine kinase inhibitors (TKIs) are approved, and are the standard of care for CML. TKIs have transformed most cases of the disease into a manageable, chronic condition. As a result, patients survival rates and the prevalence of CML are increasing, placing a growing burden on global healthcare systems.

Japan is the second-largest CML market of the 7MM, due to a high prevalence of CML, exceptionally high drug treatment rates and rapid uptake of premium-priced second-generatio <br><br>Original Post <a href=http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-japan-drug-forecast-and-market-analysis-to-2022-report.html>PharmaPoint: Chronic Myeloid Leukemia (CML) - Japan Drug Forecast and Market Analysis to 2022</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmapoint-chronic-myeloid-leukemia-cml-japan-drug-forecast-and-market-analysis-to-2022-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Ascites Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/ascites-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/ascites-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/ascites-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Ascites Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Ascites Global Clinical Trials Review, H1, 2013" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




Data <br><br>Original Post <a href=http://www.researchmoz.com/ascites-global-clinical-trials-review-h1-2013-report.html>Ascites Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Ascites Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Ascites Global Clinical Trials Review, H1, 2013" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ascites. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




Data <br><br>Original Post <a href=http://www.researchmoz.com/ascites-global-clinical-trials-review-h1-2013-report.html>Ascites Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/ascites-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cancer Pain Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/cancer-pain-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/cancer-pain-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cancer-pain-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Cancer Pain Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Cancer Pain Global Clinical Trials Review, H1, 2013" provides data on the Cancer Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 <br><br>Original Post <a href=http://www.researchmoz.com/cancer-pain-global-clinical-trials-review-h1-2013-report.html>Cancer Pain Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Cancer Pain Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Cancer Pain Global Clinical Trials Review, H1, 2013" provides data on the Cancer Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cancer Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cancer Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 <br><br>Original Post <a href=http://www.researchmoz.com/cancer-pain-global-clinical-trials-review-h1-2013-report.html>Cancer Pain Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cancer-pain-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Inflammatory Pain Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/inflammatory-pain-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/inflammatory-pain-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/inflammatory-pain-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Inflammatory Pain Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Inflammatory Pain Global Clinical Trials Review, H1, 2013" provides data on the Inflammatory Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inflammatory Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inflammatory Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data <br><br>Original Post <a href=http://www.researchmoz.com/inflammatory-pain-global-clinical-trials-review-h1-2013-report.html>Inflammatory Pain Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Inflammatory Pain Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Inflammatory Pain Global Clinical Trials Review, H1, 2013" provides data on the Inflammatory Pain clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Inflammatory Pain. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Inflammatory Pain. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data <br><br>Original Post <a href=http://www.researchmoz.com/inflammatory-pain-global-clinical-trials-review-h1-2013-report.html>Inflammatory Pain Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/inflammatory-pain-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players</title><link>http://www.researchmoz.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-report.html</link><comments>http://www.researchmoz.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-report.html#comments</comments><pubDate>Mon, 29 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-report.html</guid><description><![CDATA[

Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players

Summary

GBI Research, the leading business intelligence provider, has released its latest research &ldquo;Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players&rdquo;. Japan&rsquo;s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.

Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the incre <br><br>Original Post <a href=http://www.researchmoz.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-report.html>Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players

Summary

GBI Research, the leading business intelligence provider, has released its latest research &ldquo;Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players&rdquo;. Japan&rsquo;s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.

Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the incre <br><br>Original Post <a href=http://www.researchmoz.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-report.html>Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/japan-pharmaceutical-market-outlook-deregulation-and-more-efficient-new-drug-approval-process-attract-foreign-investment-and-improve-the-competitiveness-of-japanese-players-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Deep Brain Stimulator Market 2012-2016</title><link>http://www.researchmoz.com/global-deep-brain-stimulator-market-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-deep-brain-stimulator-market-2012-2016-report.html#comments</comments><pubDate>Fri, 26 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-deep-brain-stimulator-market-2012-2016-report.html</guid><description><![CDATA[
TechNavio's analysts forecast the Global Deep Brain Stimulator market to grow at a CAGR of 16.99 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapidly increasing awareness about deep brain stimulation devices in the US. The Global Deep Brain Stimulator market has also been witnessing the emergence of less invasive and non-invasive treatments. However, the high cost of deep brain stimulation treatment could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Deep Brain Stimulator Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Deep Brain Stimulator market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Boston Sci <br><br>Original Post <a href=http://www.researchmoz.com/global-deep-brain-stimulator-market-2012-2016-report.html>Global Deep Brain Stimulator Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
TechNavio's analysts forecast the Global Deep Brain Stimulator market to grow at a CAGR of 16.99 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapidly increasing awareness about deep brain stimulation devices in the US. The Global Deep Brain Stimulator market has also been witnessing the emergence of less invasive and non-invasive treatments. However, the high cost of deep brain stimulation treatment could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Deep Brain Stimulator Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Deep Brain Stimulator market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Boston Sci <br><br>Original Post <a href=http://www.researchmoz.com/global-deep-brain-stimulator-market-2012-2016-report.html>Global Deep Brain Stimulator Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-deep-brain-stimulator-market-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Hair Care Market 2012-2016</title><link>http://www.researchmoz.com/global-hair-care-market-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-hair-care-market-2012-2016-report.html#comments</comments><pubDate>Fri, 26 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-hair-care-market-2012-2016-report.html</guid><description><![CDATA[
TechNavio's analysts forecast the Global Hair Care market to grow at a CAGR of 6.6 percent over the period 2012-2016. One of the key factors contributing to this market growth is increasing hair and scalp problems. The Global Hair Care market has also been witnessing the emergence of online retail for hair care products. However, the intense competition among vendors could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Hair Care Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Hair Care market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Procter and Gamble Co., L'Oreal SA, and Unilever Group.

The other vendors mentioned in the report are Beiersdorf AG, Estee Lauder Com <br><br>Original Post <a href=http://www.researchmoz.com/global-hair-care-market-2012-2016-report.html>Global Hair Care Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
TechNavio's analysts forecast the Global Hair Care market to grow at a CAGR of 6.6 percent over the period 2012-2016. One of the key factors contributing to this market growth is increasing hair and scalp problems. The Global Hair Care market has also been witnessing the emergence of online retail for hair care products. However, the intense competition among vendors could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Hair Care Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Hair Care market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Procter and Gamble Co., L'Oreal SA, and Unilever Group.

The other vendors mentioned in the report are Beiersdorf AG, Estee Lauder Com <br><br>Original Post <a href=http://www.researchmoz.com/global-hair-care-market-2012-2016-report.html>Global Hair Care Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-hair-care-market-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Advanced Wound Management Market 2012-2016</title><link>http://www.researchmoz.com/global-advanced-wound-management-market-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-advanced-wound-management-market-2012-2016-report.html#comments</comments><pubDate>Fri, 26 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-advanced-wound-management-market-2012-2016-report.html</guid><description><![CDATA[
TechNavio's analysts forecast the Global Advanced Wound Management market to grow at a CAGR of 4.24 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of diabetes and obesity. The Global Advanced Wound Management market has also been witnessing the Increasing Adoption of Nanotechnology in Wound Dressing. However, the High Cost of Advanced Wound Dressings could pose a challenge to the growth of this market.

TechNavio's report, the Global Advanced Wound Management market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the moist wound care products, wound care devices, and would care biologics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Exhibit 1: &nbsp;Global Advanced Wound Management Mar <br><br>Original Post <a href=http://www.researchmoz.com/global-advanced-wound-management-market-2012-2016-report.html>Global Advanced Wound Management Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
TechNavio's analysts forecast the Global Advanced Wound Management market to grow at a CAGR of 4.24 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of diabetes and obesity. The Global Advanced Wound Management market has also been witnessing the Increasing Adoption of Nanotechnology in Wound Dressing. However, the High Cost of Advanced Wound Dressings could pose a challenge to the growth of this market.

TechNavio's report, the Global Advanced Wound Management market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC regions; it also covers the moist wound care products, wound care devices, and would care biologics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Exhibit 1: &nbsp;Global Advanced Wound Management Mar <br><br>Original Post <a href=http://www.researchmoz.com/global-advanced-wound-management-market-2012-2016-report.html>Global Advanced Wound Management Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-advanced-wound-management-market-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing &amp; Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2010 - 2017</title><link>http://www.researchmoz.com/biotechnology-market-global-forecast-market-share-size-growth-and-industry-analysis--2010-2017--report.html</link><comments>http://www.researchmoz.com/biotechnology-market-global-forecast-market-share-size-growth-and-industry-analysis--2010-2017--report.html#comments</comments><pubDate>Tue, 23 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biotechnology-market-global-forecast-market-share-size-growth-and-industry-analysis--2010-2017--report.html</guid><description><![CDATA[


The biotechnology market is expected to show substantial growth over the forecast period owing to regulatory support offered to various companies operating in the biotechnology field. In addition, the increased demand for food in developing countries has spurred the growth of the bioagriculture market. Bioseeds are expected to show exponential growth as compared to conventional seeds over the forecast period.

This report on the biotechnology market analyzes and estimates the global revenue generated by the biotechnology industry over the forecast period i.e. 2012 to 2017. The scope of the report considers biotechnology to be divided into four primary segments namely biopharmacy, bioservices, bioagriculture and bioindustrial. In terms of technology, the biotechnology market has been segmented into fermentation, tissue regeneration, PCR technology, nanobiotechnology, chromatography, DNA sequencing, cell based assay and others. The others segment comprises of genetic engineering, <br><br>Original Post <a href=http://www.researchmoz.com/biotechnology-market-global-forecast-market-share-size-growth-and-industry-analysis--2010-2017--report.html>Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing &amp; Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2010 - 2017</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[


The biotechnology market is expected to show substantial growth over the forecast period owing to regulatory support offered to various companies operating in the biotechnology field. In addition, the increased demand for food in developing countries has spurred the growth of the bioagriculture market. Bioseeds are expected to show exponential growth as compared to conventional seeds over the forecast period.

This report on the biotechnology market analyzes and estimates the global revenue generated by the biotechnology industry over the forecast period i.e. 2012 to 2017. The scope of the report considers biotechnology to be divided into four primary segments namely biopharmacy, bioservices, bioagriculture and bioindustrial. In terms of technology, the biotechnology market has been segmented into fermentation, tissue regeneration, PCR technology, nanobiotechnology, chromatography, DNA sequencing, cell based assay and others. The others segment comprises of genetic engineering, <br><br>Original Post <a href=http://www.researchmoz.com/biotechnology-market-global-forecast-market-share-size-growth-and-industry-analysis--2010-2017--report.html>Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing &amp; Others) - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2010 - 2017</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biotechnology-market-global-forecast-market-share-size-growth-and-industry-analysis--2010-2017--report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Healthcare, Regulatory and Reimbursement Landscape - Argentina</title><link>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-argentina-report.html</link><comments>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-argentina-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-argentina-report.html</guid><description><![CDATA[

Healthcare, Regulatory and Reimbursement Landscape Argentina

Summary

Industry analysis specialist GlobalData has released its latest report Healthcare, Regulatory and Reimbursement Landscape Argentina. An essential source of information and analysis on the Argentinas healthcare, regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure.

Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, Argentinas population was 41.5 million, largely due to natural population and immigrants from Europe. The pharmaceutical market was estimated to be worth $5.6 billion, in 2012 and is expecte <br><br>Original Post <a href=http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-argentina-report.html>Healthcare, Regulatory and Reimbursement Landscape - Argentina</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Healthcare, Regulatory and Reimbursement Landscape Argentina

Summary

Industry analysis specialist GlobalData has released its latest report Healthcare, Regulatory and Reimbursement Landscape Argentina. An essential source of information and analysis on the Argentinas healthcare, regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure.

Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, Argentinas population was 41.5 million, largely due to natural population and immigrants from Europe. The pharmaceutical market was estimated to be worth $5.6 billion, in 2012 and is expecte <br><br>Original Post <a href=http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-argentina-report.html>Healthcare, Regulatory and Reimbursement Landscape - Argentina</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-argentina-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Healthcare, Regulatory and Reimbursement Landscape - Belgium</title><link>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-belgium-report.html</link><comments>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-belgium-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-belgium-report.html</guid><description><![CDATA[

Healthcare, Regulatory and Reimbursement Landscape Belgium

Summary

Industry analysis specialist GlobalData has released its latest report Healthcare, Regulatory and Reimbursement Landscape Belgium. An essential source of information and analysis on the Belgian healthcare, regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure.

Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, Belgium had a population of 11 million. The pharmaceutical market was estimated to be worth $6.32 billion in 2013 at consumer-price level (including Value Added Tax (VAT) and excluding hospital sal <br><br>Original Post <a href=http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-belgium-report.html>Healthcare, Regulatory and Reimbursement Landscape - Belgium</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Healthcare, Regulatory and Reimbursement Landscape Belgium

Summary

Industry analysis specialist GlobalData has released its latest report Healthcare, Regulatory and Reimbursement Landscape Belgium. An essential source of information and analysis on the Belgian healthcare, regulatory and reimbursement landscape, it identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, and reimbursement landscape and healthcare infrastructure.

Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalDatas team of industry experts.

In 2012, Belgium had a population of 11 million. The pharmaceutical market was estimated to be worth $6.32 billion in 2013 at consumer-price level (including Value Added Tax (VAT) and excluding hospital sal <br><br>Original Post <a href=http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-belgium-report.html>Healthcare, Regulatory and Reimbursement Landscape - Belgium</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/healthcare-regulatory-and-reimbursement-landscape-belgium-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Anorexia Nervosa Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/anorexia-nervosa-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/anorexia-nervosa-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/anorexia-nervosa-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Anorexia Nervosa Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Anorexia Nervosa Global Clinical Trials Review, H1, 2013" provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for  <br><br>Original Post <a href=http://www.researchmoz.com/anorexia-nervosa-global-clinical-trials-review-h1-2013-report.html>Anorexia Nervosa Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Anorexia Nervosa Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Anorexia Nervosa Global Clinical Trials Review, H1, 2013" provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Anorexia Nervosa. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for  <br><br>Original Post <a href=http://www.researchmoz.com/anorexia-nervosa-global-clinical-trials-review-h1-2013-report.html>Anorexia Nervosa Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/anorexia-nervosa-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Delirium Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/delirium-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/delirium-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/delirium-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Delirium Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Delirium Global Clinical Trials Review, H1, 2013" provides data on the Delirium clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Delirium. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Delirium. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



D <br><br>Original Post <a href=http://www.researchmoz.com/delirium-global-clinical-trials-review-h1-2013-report.html>Delirium Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Delirium Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Delirium Global Clinical Trials Review, H1, 2013" provides data on the Delirium clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Delirium. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Delirium. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



D <br><br>Original Post <a href=http://www.researchmoz.com/delirium-global-clinical-trials-review-h1-2013-report.html>Delirium Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/delirium-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Diverticulitis Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/diverticulitis-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/diverticulitis-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/diverticulitis-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Diverticulitis Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Diverticulitis Global Clinical Trials Review, H1, 2013" provides data on the Diverticulitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diverticulitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diverticulitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indica <br><br>Original Post <a href=http://www.researchmoz.com/diverticulitis-global-clinical-trials-review-h1-2013-report.html>Diverticulitis Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Diverticulitis Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Diverticulitis Global Clinical Trials Review, H1, 2013" provides data on the Diverticulitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diverticulitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diverticulitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indica <br><br>Original Post <a href=http://www.researchmoz.com/diverticulitis-global-clinical-trials-review-h1-2013-report.html>Diverticulitis Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/diverticulitis-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Dyskinesia Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/dyskinesia-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/dyskinesia-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/dyskinesia-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Dyskinesia Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyskinesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scop <br><br>Original Post <a href=http://www.researchmoz.com/dyskinesia-global-clinical-trials-review-h1-2013-report.html>Dyskinesia Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Dyskinesia Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyskinesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scop <br><br>Original Post <a href=http://www.researchmoz.com/dyskinesia-global-clinical-trials-review-h1-2013-report.html>Dyskinesia Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/dyskinesia-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Dystonia Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/dystonia-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/dystonia-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/dystonia-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Dystonia Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Dystonia Global Clinical Trials Review, H1, 2013" provides data on the Dystonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dystonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dystonia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



D <br><br>Original Post <a href=http://www.researchmoz.com/dystonia-global-clinical-trials-review-h1-2013-report.html>Dystonia Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Dystonia Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Dystonia Global Clinical Trials Review, H1, 2013" provides data on the Dystonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dystonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dystonia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



D <br><br>Original Post <a href=http://www.researchmoz.com/dystonia-global-clinical-trials-review-h1-2013-report.html>Dystonia Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/dystonia-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Radiculopathy Global Clinical Trials Review, H1, 2013</title><link>http://www.researchmoz.com/radiculopathy-global-clinical-trials-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/radiculopathy-global-clinical-trials-review-h1-2013-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/radiculopathy-global-clinical-trials-review-h1-2013-report.html</guid><description><![CDATA[

Radiculopathy Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Radiculopathy Global Clinical Trials Review, H1, 2013" provides data on the Radiculopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Radiculopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Radiculopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated d <br><br>Original Post <a href=http://www.researchmoz.com/radiculopathy-global-clinical-trials-review-h1-2013-report.html>Radiculopathy Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Radiculopathy Global Clinical Trials Review, H1, 2013

Summary

GlobalData's clinical trial report, Radiculopathy Global Clinical Trials Review, H1, 2013" provides data on the Radiculopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Radiculopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Radiculopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated d <br><br>Original Post <a href=http://www.researchmoz.com/radiculopathy-global-clinical-trials-review-h1-2013-report.html>Radiculopathy Global Clinical Trials Review, H1, 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/radiculopathy-global-clinical-trials-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies &amp; Deal Synergies between Academia and the Pharmaceutical Industry</title><link>http://www.researchmoz.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-and-deal-synergies-between-academia-and-the-pharmaceutical-industry-report.html</link><comments>http://www.researchmoz.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-and-deal-synergies-between-academia-and-the-pharmaceutical-industry-report.html#comments</comments><pubDate>Mon, 22 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-and-deal-synergies-between-academia-and-the-pharmaceutical-industry-report.html</guid><description><![CDATA[

PharmaSphere: Early-Stage Technology Transfer Collaborations Enabling Platform Technologies &amp; Deal Synergies between Academia and the Pharmaceutical Industry

Summary

The PharmaSphere, Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 20122013. GlobalDatas Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industrys attempts at moving toward an open R&amp;D ecosystem.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding wee <br><br>Original Post <a href=http://www.researchmoz.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-and-deal-synergies-between-academia-and-the-pharmaceutical-industry-report.html>PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies &amp; Deal Synergies between Academia and the Pharmaceutical Industry</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

PharmaSphere: Early-Stage Technology Transfer Collaborations Enabling Platform Technologies &amp; Deal Synergies between Academia and the Pharmaceutical Industry

Summary

The PharmaSphere, Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 20122013. GlobalDatas Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industrys attempts at moving toward an open R&amp;D ecosystem.

Note: This is upcoming report and will be delivered within 24 hrs of the purchase (excluding wee <br><br>Original Post <a href=http://www.researchmoz.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-and-deal-synergies-between-academia-and-the-pharmaceutical-industry-report.html>PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies &amp; Deal Synergies between Academia and the Pharmaceutical Industry</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pharmasphere-early-stage-technology-transfer-collaborations-enabling-platform-technologies-and-deal-synergies-between-academia-and-the-pharmaceutical-industry-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Chiral Technology Market 2012-2016</title><link>http://www.researchmoz.com/global-chiral-technology-market-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-chiral-technology-market-2012-2016-report.html#comments</comments><pubDate>Fri, 19 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-chiral-technology-market-2012-2016-report.html</guid><description><![CDATA[
TechNavio's analysts forecast the Global Chiral Technology market to grow at a CAGR of 6.6 percent over the period 2012-2016. One of the key factors contributing to this market growth is favorable government regulations for chiral technology. The Global Chiral Technology market has also been witnessing increasing reliance on generic approaches. However, the slow commercialization of chiral technology-based products could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Chiral Technology Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. &nbsp;The report covers the Americas, and the EMEA and APAC regions; it covers the Global Chiral Technology market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. &nbsp;

The key vendors dominating this space are Daicel Corp., Chiral Technologies, Royal DSM N.V., and Sig <br><br>Original Post <a href=http://www.researchmoz.com/global-chiral-technology-market-2012-2016-report.html>Global Chiral Technology Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
TechNavio's analysts forecast the Global Chiral Technology market to grow at a CAGR of 6.6 percent over the period 2012-2016. One of the key factors contributing to this market growth is favorable government regulations for chiral technology. The Global Chiral Technology market has also been witnessing increasing reliance on generic approaches. However, the slow commercialization of chiral technology-based products could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Chiral Technology Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. &nbsp;The report covers the Americas, and the EMEA and APAC regions; it covers the Global Chiral Technology market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. &nbsp;

The key vendors dominating this space are Daicel Corp., Chiral Technologies, Royal DSM N.V., and Sig <br><br>Original Post <a href=http://www.researchmoz.com/global-chiral-technology-market-2012-2016-report.html>Global Chiral Technology Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-chiral-technology-market-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Proteomics Market 2012-2016</title><link>http://www.researchmoz.com/global-proteomics-market-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-proteomics-market-2012-2016-report.html#comments</comments><pubDate>Fri, 19 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-proteomics-market-2012-2016-report.html</guid><description><![CDATA[
TechNavio's analysts forecast the Global Proteomics market to grow at a CAGR of 14.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Proteomics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Proteomics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Thermo Fischer Scientific Inc., Agilent Technologies Inc., Life Technologies Corp., and Danaher Corp.
The other vendors mentioned in  <br><br>Original Post <a href=http://www.researchmoz.com/global-proteomics-market-2012-2016-report.html>Global Proteomics Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
TechNavio's analysts forecast the Global Proteomics market to grow at a CAGR of 14.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicines. The Global Proteomics market has also been witnessing a shift from genomics to proteomics. However, the intense competition among vendors could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Proteomics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Proteomics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this space are Thermo Fischer Scientific Inc., Agilent Technologies Inc., Life Technologies Corp., and Danaher Corp.
The other vendors mentioned in  <br><br>Original Post <a href=http://www.researchmoz.com/global-proteomics-market-2012-2016-report.html>Global Proteomics Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-proteomics-market-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Global Atherectomy and Thrombectomy Devices Market 2012-2016</title><link>http://www.researchmoz.com/global-atherectomy-and-thrombectomy-devices-market-2012-2016-report.html</link><comments>http://www.researchmoz.com/global-atherectomy-and-thrombectomy-devices-market-2012-2016-report.html#comments</comments><pubDate>Fri, 19 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/global-atherectomy-and-thrombectomy-devices-market-2012-2016-report.html</guid><description><![CDATA[
TechNavio's analysts forecast the Global Atherectomy Devices market to grow at a CAGR of 11.48 percent and the Global Thrombectomy Devices market to grow at a CAGR of 8.14 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of Abdominal Aortic Aneurysm and &nbsp;Peripheral Arterial Disease worldwide.&nbsp;

The Global Atherectomy and Thrombectomy Devices market has also been witnessing an increase in patent grants and US FDA approvals. However, the adverse effects of atherectomy and thrombectomy devices could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Atherectomy and Thrombectomy Devices Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Atherectomy and Thrombectomy Devices market landscape and its growth prospects in the  <br><br>Original Post <a href=http://www.researchmoz.com/global-atherectomy-and-thrombectomy-devices-market-2012-2016-report.html>Global Atherectomy and Thrombectomy Devices Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
TechNavio's analysts forecast the Global Atherectomy Devices market to grow at a CAGR of 11.48 percent and the Global Thrombectomy Devices market to grow at a CAGR of 8.14 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing incidence of Abdominal Aortic Aneurysm and &nbsp;Peripheral Arterial Disease worldwide.&nbsp;

The Global Atherectomy and Thrombectomy Devices market has also been witnessing an increase in patent grants and US FDA approvals. However, the adverse effects of atherectomy and thrombectomy devices could pose a challenge to the growth of this market.&nbsp;

TechNavio's report, Global Atherectomy and Thrombectomy Devices Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Atherectomy and Thrombectomy Devices market landscape and its growth prospects in the  <br><br>Original Post <a href=http://www.researchmoz.com/global-atherectomy-and-thrombectomy-devices-market-2012-2016-report.html>Global Atherectomy and Thrombectomy Devices Market 2012-2016</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/global-atherectomy-and-thrombectomy-devices-market-2012-2016-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of  <br><br>Original Post <a href=http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html>Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of  <br><br>Original Post <a href=http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html>Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snaps <br><br>Original Post <a href=http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html>Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snaps <br><br>Original Post <a href=http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html>Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Burns -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Burns -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Burns - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Burns.- A review of the Burns products under development  <br><br>Original Post <a href=http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html>Burns -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Burns -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Burns - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Burns.- A review of the Burns products under development  <br><br>Original Post <a href=http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html>Burns -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Indolent Lymphoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Indolent Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html>Indolent Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Indolent Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html>Indolent Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Myelofibrosis -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Myelofibrosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Myelofibrosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis. Myelofibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Myelofibrosis.- A <br><br>Original Post <a href=http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html>Myelofibrosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Myelofibrosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Myelofibrosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis. Myelofibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Myelofibrosis.- A <br><br>Original Post <a href=http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html>Myelofibrosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Osteosarcoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Osteosarcoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Osteosarcoma.- A revie <br><br>Original Post <a href=http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html>Osteosarcoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Osteosarcoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Osteosarcoma.- A revie <br><br>Original Post <a href=http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html>Osteosarcoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Psychiatric Disorders -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Psychiatric Disorders -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global th <br><br>Original Post <a href=http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html>Psychiatric Disorders -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Psychiatric Disorders -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global th <br><br>Original Post <a href=http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html>Psychiatric Disorders -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated di <br><br>Original Post <a href=http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html>Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated di <br><br>Original Post <a href=http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html>Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Post Menopausal Osteoporosis -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Post Menopausal Osteoporosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html>Post Menopausal Osteoporosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Post Menopausal Osteoporosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html>Post Menopausal Osteoporosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability an <br><br>Original Post <a href=http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html>Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability an <br><br>Original Post <a href=http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html>Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item></channel></rss>